Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

NAVIDEA BIOPHARMACEUTICALS INC (NAVB)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Navidea Biopharmaceuticals : Management to Host Moderated Q&A Webcast to Provide Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 11:48pm CEST

Webcast will also focus on Proxy Updates

Navidea Biopharmaceuticals (NYSE American: NAVB) (Navidea or The Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that it will hold an online Question & Answer (Q&A) Session focused on Navidea’s corporate progress as well as an update on the corporate proxy with Jed Latkin, Chief Financial and Operating Officer, and Michael M. Goldberg, M.D., President and Chief Executive Officer of Navidea, on Thursday July 19, 2018 at 5:00 p.m. Eastern Time.

 
Event: Navidea IR Q&A Session – July 2018
Date: Thursday, July 19, 2018
Time: 5:00 p.m. Eastern Time
Website:

www.navidea.com

For the July IR-focused Q&A Session, Navidea invites all interested investors to submit questions they would like to see asked by Wednesday, July 18, 2018 to [email protected] or [email protected].

Details for the webcast link will be made available on the Investor Relations section of Navidea’s website at www.navidea.com.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc 99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. The development activities of the Manocept immunotherapeutic platform are being conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.

For more information, please visit http://www.navidea.com.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NAVIDEA BIOPHARMACEUTICALS
07/16NAVIDEA BIOPHARMACEUTICALS : Management to Host Moderated Q&A Webcast to Provide..
AQ
07/12NAVIDEA BIOPHARMACEUTICALS : Management to Host Moderated Q&A Webcast to Provide..
BU
06/14NAVIDEA BIOPHARMACEUTICALS : to Host Moderated Q&A Webcast with Management
BU
05/30NAVIDEA BIOPHARMACEUTICALS : to Present at 8th Annual LD Micro Invitational Conf..
BU
05/15NAVIDEA BIOPHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/09NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
AQ
05/09NAVIDEA : 1Q Earnings Snapshot
AQ
05/08NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
AQ
05/08NAVIDEA BIOPHARMACEUTICALS : Reports First Quarter 2018 Financial Results
BU
05/08NAVIDEA BIOPHARMACEUTICALS : Schedules First Quarter 2018 Earnings Conference Ca..
AQ
More news
News from SeekingAlpha
05/09Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q1 2018 Results - .. 
05/08Navidea Biopharm reports Q1 results 
05/02Cirius Therapeutics completes enrollment in mid-stage study of lead candidate.. 
04/20Key events next week - healthcare 
04/16Navidea signs deal to sublicense NAV4694 worldwide development rights 
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Income Statement Evolution
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Jed Andrew Latkin CFO, COO, Secretary & Treasurer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Mark I. Greene Independent Director
Michael Yehuda Rice Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTICALS INC-41.42%34
CELLTRION, INC.--.--%32 245
IQVIA HOLDINGS INC13.49%22 746
LONZA GROUP8.17%21 355
INCYTE CORPORATION-25.97%14 861
SEATTLE GENETICS, INC.31.33%11 158